Gene editing using CRISPR reduces autism symptoms in mice

Gene editing using CRISPR reduces autism symptoms in mice

Scientists have edited a gene in the brain to decrease the repetitive behaviors of mice with fragile X syndrome, which is an inherited cause of autism spectrum disorders. The study is described in the journal Nature Biomedical Engineering.

The researchers used nanoparticle carriers developed in California to inject a gene-editing enzyme called Cas9 into the striatum, a brain region associated with formation of habits.

Enzymes are proteins that trigger biochemical reactions. "The enzyme we used, Cas9, is like a pair of scissors," said the senior author. "We were able to cut the genetic blueprint, DNA, at a location that causes the exaggerated repetitive behaviors."

The researchers targeted Cas9 at a molecule called mGluR5 that is excitatory--it increases communications between neurons. The approach worked. The rodents' digging behavior slowed by 30 percent and the leaping behavior was reduced by 70 percent. In the process, the research revealed valuable information about mGluR5's function, the senior author said.

The team is believed to be the first to successfully edit a causal gene for autism in the brain and diminish symptoms, the authors wrote. Significantly, the effect is permanent, the author said.

The study is also one of the first in the scientific literature to employ a safer, non-viral approach of Cas9 delivery to a brain region.

"Previous attempts by other groups used viral carriers to convey Cas9, which has potential problems because the virus can't be programmed to stop working," said the first author. "This can result in serious immune reactions and cell toxicity."